AMRX - Latest News

Amneal Pharmaceuticals, Inc. (AMRX), operates in Healthcare / Drug Manufacturers - Specialty & Generic, trades on NASDAQ.

Market capitalization stands near $5.50B. Trailing twelve-month P/E ratio is 46.32. Beta to the broader market is 1.32.

The article list below shows the most recent AMRX headlines from major financial news vendors. For options traders, the most actionable items are earnings releases, analyst rating changes, M&A activity, and regulatory filings - each can drive a meaningful repricing of implied volatility and shift dealer hedging flow. Pair the news context with the implied-volatility skew and gamma exposure views to see whether the options market has already priced in the headline.

Recent AMRX Headlines

Zambon and Amneal Announce Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations

globenewswire.com - Jun 29, 2026

MILAN and BRIDGEWATER, N. J.

Why Amneal Pharmaceuticals (AMRX) is a Top Momentum Stock for the Long-Term

zacks.com - Jun 24, 2026

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Pre

The Healthcare M&A Wave

forbes.com - Jun 17, 2026

In this week's edition of InnovationRx, we look at biotech M&A, the rise of India's Anthem Biosciences, and more. To get it in your inbox, subscribe

AMNEAL PHARMACEUTICALS, INC. (AMRX) Hits Fresh High: Is There Still Room to Run?

zacks.com - Jun 11, 2026

Amneal (AMRX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Is Amneal Pharmaceuticals Inc (AMRX) Overvalued After 4.4% Rally? GF Value Says Overvalued

gurufocus.com - Jun 10, 2026

On June 10, 2026, Amneal Pharmaceuticals Inc (AMRX) shares rose 4. 4% today, bringing the current price to $15.

How News Affects AMRX Options Pricing

Headlines and scheduled events drive implied volatility in two distinct ways. Pre-event, IV typically inflates as uncertainty about the outcome rises; this is the implied-volatility expansion that creates the long-vol setup. Post-event, IV typically contracts sharply as uncertainty resolves; this is IV crush, which makes premium-selling structures profitable when they survive the underlying move. The size of the crush depends on how stretched pre-event IV is relative to the realized move. Track AMRX's implied vs realized volatility over the news cycle to size pre-event vs post-event positioning. For ticker-level dealer positioning context, the gamma exposure view shows whether dealers are positioned to amplify or dampen post-news moves.

Frequently asked AMRX news questions

What is the latest AMRX news headline?

The most recent AMRX headline (Jun 29, 2026) is "Zambon and Amneal Announce Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations". The five most recent stories with summaries and publication times are listed above, sourced from major financial news vendors.

How fresh is the AMRX news on this page?

News rows refresh roughly every 30 minutes during the trading day. The five most recent headlines are listed in publication-time order. Press releases from the company itself typically appear within minutes of the wire release; third-party reporting may lag by 30-60 minutes depending on the source.

What AMRX news moves options pricing?

Three categories move single-name IV most aggressively: scheduled earnings releases (priced into pre-event IV, crushed post-event), unscheduled M&A or strategic announcements (rapid IV expansion, slower decay), and regulatory or legal events (drug-trial readouts, antitrust filings, FDA approvals). Routine news flow (analyst commentary, sector rotation) typically does not move IV meaningfully unless it triggers a cluster of rating changes.

How can I track unusual AMRX options activity related to news?

Unusual options activity often precedes news by hours to days; the canonical signals are volume substantially above the trailing average concentrated in a small number of strikes, atypical put/call skew, and aggressive execution (at-the-ask sweeps or block prints). Cross-reference the per-ticker gamma-exposure and volume-history pages with the news flow above to triangulate informed vs uninformed flow.